A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)

Inclusion criteria

• Has radiographically measurable disease per protocol
• If to receive oral study treatment, has the ability to swallow and retain oral medication and does not have gastrointestinal abnormalities that may alter absorption
• Has well-controlled human immunodeficiency virus (HIV) on antiretroviral therapy (ART) if diagnosed with HIV
• Has adequate organ function per protocol

Exclusion criteria

• Has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease if diagnosed with HIV
• Has a history of posterior reversible encephalopathy syndrome (PRES) or seizure disorder
• Has hepatic encephalopathy, hepatorenal syndrome, or Child-Pugh class B or more severe liver cirrhosis
• Has a history of confirmed inflammatory bowel disease
• Has a serious active nonhealing wound, ulcer, and/or bone fracture
• Has a history of myocarditis or cardiomyopathy
• Has a history of or current severe cardiovascular and cerebrovascular diseases
• Is currently receiving any anticoagulants
• Has a diagnosis of immunodeficiency
• Has a known additional malignancy that is progressing or required active treatment within the past 3 years
• Has known active central nervous system metastases and/or carcinomatous meningitis
• Has active autoimmune disease that required systemic treatment in the past 2 years (hormonal supplementation [eg, thyroxine, insulin, or physiologic corticosteroid] is allowed)
• Has a history of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids or has current pneumonitis/ILD
• Has a history of stem cell/solid organ transplant
• Has not adequately recovered from major surgery or from central venous access device placement, or has ongoing surgical complications